NEW YORK (Reuters) – Mylan N.V.’s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment’s manufacturer said on Friday.
NEW YORK (Reuters) – Mylan N.V.’s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment’s manufacturer said on Friday.
Comments are closed, but trackbacks and pingbacks are open.